My name is Drew.

Drew's portrait

I’m a college student — and a college athlete. I’m not letting PNH stop me. This is my story.

1     2     3     Next

Twenty-year-old Drew’s dream was to pitch baseball at the college level, but this was almost unattainable when he learned he had paroxysmal nocturnal hemoglobinuria (PNH). After a hard time of trying to control his disease, Drew now has more energy thanks to Soliris®, and he’s finally getting a chance to live his dream.

Drew is a college student who loves to play baseball. As with any sport, the requirements are year-round, but it hasn’t always been easy for Drew to keep up with the demands of his college academics and sports. In fact, at times, it was almost impossible. Drew has PNH — a rare, potentially life-threatening disease that destroys red blood cells through a process called hemolysis.1-3 Essentially, Drew’s body attacks its own red blood cells, often making him so exhausted that he has difficulty functioning like others his own age.

In the fall of 2005, before he had even heard of PNH, Drew was struggling through his freshman year. He was always tired. Practically all he wanted to do was sleep. He found himself sleeping through his classes, sleeping through his study time, and even sleeping through his workouts.

Not only were his grades slipping, so were his dreams of pitching at the college level. It got worse when Drew noticed his urine was dark and red. Though he suspected that none of these symptoms seemed normal for a young, healthy athlete like himself, Drew simply attributed them to the rigors of his training. After all, there were times when Drew felt fine. His urine was dark only after his workouts, and he was certainly pushing himself to perform, so he decided to tough it out and not think about it.

Then in March of 2006, he had no choice but to think about it. While practicing for a game, Drew passed out cold. Not one to give up, he arrived to pitch the following day, but his trainer knew better.

1     2     3     Next





IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early

  • Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
  • Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary

The effect of anticoagulant withdrawal during Soliris treatment has not been studied. Therefore, treatment with Soliris should not alter anticoagulant management.

Soliris is generally well tolerated. The most frequent adverse events observed in clinical studies were headache, a runny nose (nasopharyngitis), back pain, nausea, and tiredness (fatigue).

Please see full prescribing information for SOLIRIS, including boxed WARNING regarding serious meningitis.


References: 1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258. 2. Socié G, Mary J-Y, de Gramont A, et al; for the French Society of Haematology. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996;348:573-577. 3. Nishimura J-I, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine. 2004;83:193-207. 4. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243. 5. de Castro CM. Paroxysmal Nocturnal Hemoglobinuria (PNH) Basic Explanations. Annapolis, MD: Aplastic Anemia & MDS International Foundation; 2006.